Ribavirin

Known as: RTCA, Ribovirin, RBV 
A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Background Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
The recommended treatment for patients with chronic hepatitis C, pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV), does… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin… (More)
  • figure 1
  • table 1
  • table 3
Is this relevant?
Review
2005
Review
2005
Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment… (More)
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2000
Highly Cited
2000
This paper focuses on dynamic capabilities and, more generally, the resource-based view of the firm. We argue that dynamic… (More)
  • table 1
  • table 2
Is this relevant?